Core Insights - Predictive Oncology Inc. announced positive results from a study in collaboration with Tecan, presented at the 2025 SLAS International Conference, focusing on the use of patient-derived tumor spheroids for drug discovery [1][4] Group 1: Company Overview - Predictive Oncology is a leader in AI-driven drug discovery and biologics, utilizing a vast biobank of cryopreserved live cell tumor specimens [1][9] - The company’s AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds, enhancing drug selection processes [9] - Tecan, a partner in the study, is a global leader in laboratory automation, with 2023 sales of CHF 1,074 million (approximately USD 1,194 million) [7] Group 2: Research and Development - The study utilized patient-derived tumor models (PDTMs) to develop personalized therapies, addressing challenges in accessibility and scalability of primary tumor cells through cryopreserved dissociated tumor cells (DTCs) [2][5] - Optimized growth conditions and drug treatment protocols were established for tumor models derived from cryopreserved DTCs, demonstrating that 3D models are more representative of in vivo conditions compared to 2D models [3] - The research highlights the importance of monitoring tumor growth and drug response through advanced imaging techniques and automated analysis [6] Group 3: Market Insights - The high throughput screening (HTS) market is projected to reach $69.5 billion by 2032, with a compound annual growth rate (CAGR) of 12.18%, driven by the adoption of 3D cell cultures and organoids [4]
Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis